Skip to main content
Marisa Miceli, MD, Infectious Disease, Ann Arbor, MI, University of Michigan Medical Center

MarisaHaydeeMiceliMD

Infectious Disease • Ann Arbor, MI

Physician

Join to view full profile

Dr. Miceli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Miceli's full profile

Already have an account?

  • Office

    1500 East Medical Center Dr
    3rd Floor Taubman Center Recp D
    Ann Arbor, MI 48109
    Phone+1 734-936-5899
    Fax+1 734-615-2156
  • Is this information wrong?

Education & Training

  • Beaumont Health (Dearborn)
    Beaumont Health (Dearborn)Residency, Internal Medicine, 2009 - 2012
  • University of New Mexico School of Medicine
    University of New Mexico School of MedicineFellowship, Infectious Disease, 2007 - 2009
  • University of Buenos Aires
    University of Buenos AiresClass of 1992

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2009 - 2025
  • NM State Medical License
    NM State Medical License 2007 - 2009
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Publications & Presentations

PubMed

Press Mentions

  • Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. Mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID
    Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. Mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMIDApril 18th, 2023
  • Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
    Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 23rd, 2024
  • Patient with Candida Krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
    Patient with Candida Krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical ResolutionOctober 12th, 2023

Hospital Affiliations

Dr. Marisa Miceli, Dr. Marisa Miceli, MD, Dr. M Miceli, Dr. Marisa Haydee Miceli